MabGenesis Inc. (TYO:653A)
635.00
-31.00 (-4.65%)
Nov 18, 2026, 11:09 AM JST
MabGenesis Company Description
MabGenesis Inc., a biopharmaceutical company, engages in the research, discovery, development, and commercialization of therapeutic monoclonal antibody drugs for human and animal healthcare applications in Japan.
The company offers proprietary antibody discovery platforms, including MOURA Libraries and IMPACT antibody isolation technology, to develop antibody therapeutics.
The company was incorporated in 2019 and is based in Yokohama, Japan.
MabGenesis Inc.
| Country | Japan |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Katsuhiro Shinjo |
Contact Details
Address: 3 Chome-7-18 Shinyokohama Yokohama, 222-0033 Japan | |
| Phone | 81 45 534 6033 |
| Website | mabgenesis.com |
Stock Details
| Ticker Symbol | 653A |
| Exchange | Tokyo Stock Exchange |
| Stock Type | Common Stock |
| Reporting Currency | JPY |
| ISIN Number | JP3870010000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Katsuhiro Shinjo | Chief Executive Officer |